Enterprise Value
156.6M
Cash
18.97M
Avg Qtr Burn
-368.3K
Short % of Float
9.34%
Insider Ownership
1.21%
Institutional Own.
52.90%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Onivyde® (irinotecan liposome injection) + 5 fluorouracil/leucovorin+ oxaliplatin Details Pancreatic cancer, Cancer | PDUFA Approval decision | |
Onivyde® (irinotecan liposome injection) Details Cancer, Small cell lung cancer, Lung cancer | Phase 3 Update |